Abbott Laboratories
ABT · US
ABT Research Preview
---
| Metric | Value | Interpretation |
|---|---|---|
| Price | $103.06 | +2.29% daily |
| Score | 64 / 100 | Buy signal, bullish trend |
| Trend | Bull | MA5 > MA10 > MA20 > MA60 |
| RSI14 | 62.70 | Constructive, not extreme |
| MACD histogram | +0.54 | Positive, expanding |
| Estimated support | $86.72 | Bollinger lower band |
| Estimated resistance | $94.68 | Bollinger upper band (now breached) |
| 30-session range position | 167.9% | Well above prior range ceiling |
| Volume vs 20-day avg | -26.04% | Below-average participation |
| Data confidence | Medium | Fundamentals from SEC; no social sentiment |
---
| Indicator | Reading | Signal | Notes |
|---|---|---|---|
| **MA structure** | MA5 93.03 > MA10 91.56 > MA20 90.70 > MA60 90.62 | Bullish | Full bullish alignment; price 13.6% above MA20 |
| **RSI14 / RSI6** | 62.70 / 70.48 | Constructive | RSI6 elevated but RSI14 not yet overbought (>70) |
| **MACD** | Line 1.07, Signal 0.54, Hist +0.54 | Bullish | Golden cross intact; histogram expanding |
| **KDJ** | K 72.83, D 64.90, J 88.68 | Bullish | J-line extended; watch for K/D rollover |
| **Bollinger Bands** | Upper 94.68 / Mid 90.70 / Lower 86.72 | Overbought | Price 205% of band width above midline |
| **ATR14** | 2.68 (2.81% of price) | Moderate | Typical daily range ~$2.70; volatility normal |
| **OBV** | -322 M, 20-day slope +3.01% | Neutral | Slight accumulation trend but absolute level negative |
| **CCI20** | 151.88 | Overbought | >100 indicates strong momentum; >150 often precedes pause |
Confirmed: Trend direction (bullish MA stack, MACD, KDJ) and momentum (CCI, RSI6).
Conflicted: Volume-price divergence-price rising on below-average volume suggests limited institutional conviction. OBV slope is mildly positive, but absolute OBV remains negative, indicating longer-term distribution backdrop.
Missing: No custom indicators were supplied. Social-sentiment and options-flow data are unavailable, limiting insight into positioning.
---
| Metric | Value | Source | Confidence |
|---|---|---|---|
| PE | 27.61 | SEC EDGAR | Medium |
| PB | 3.46 | SEC EDGAR | Medium |
| Price / Sales | 4.06 | SEC EDGAR | Medium |
| EV / EBITDA | 25.75 | SEC EDGAR | Low |
| StockKit fair-value range | Bear $34.29 / Base $44.91 / Bull $58.25 | StockKit DCF scenario model | Medium |
| Base fair-value gap | -56.4% | StockKit DCF scenario model | Medium |
| 5Y growth forecast | Bear -8.0% / Base -2.0% / Bull +4.0% | StockKit scenario model | Medium |
| Revenue (FY 2025) | $44.33 B | SEC EDGAR | High |
| Net income (FY 2025) | $6.52 B | SEC EDGAR | High |
| Market cap | $180.15 B | SEC shares outstanding + quote | Medium |
| Balance sheet | Assets $110.43 B / Equity $52.06 B | SEC EDGAR | High |
Interpretation: At $103, ABT trades at a 56% premium to the StockKit base-case DCF of $44.91. Even the bull-case fair value ($58.25) implies significant overvaluation. Traditional multiples (PE 27.6×, EV/EBITDA 25.8×) are elevated relative to the modeled low-single-digit growth trajectory. This does not preclude further price appreciation driven by momentum or sentiment, but it does raise the risk/reward bar for new long exposure.
---
| Date | Headline | Relevance |
|---|---|---|
| 2026-07-26 | Çinar Basmaci, CEO de Kentkart… (Expansion.com) | **Not relevant** to Abbott Laboratories |
| 2026-07-26 | DTM race Oschersleben 2… (Motorsport.com) | **Not relevant** |
| 2026-07-26 | DTM Oschersleben: Preining on pole… (Motorsport.com) | **Not relevant** |
| 2026-07-26 | Fórmula E: Mortara supera Da Costa… (Terra.com.br) | **Not relevant** |
| 2026-07-26 | PEZ Bookshelf: Off to the Races (PezCycling News) | **Not relevant** |
Assessment: None of the five headlines pertain to Abbott Laboratories. The news feed appears to have returned unrelated content, likely due to a data-retrieval mismatch. Consequently, no company-specific catalyst can be confirmed from the supplied news data. Investors should independently verify upcoming earnings dates, FDA decisions, or product launches via Abbott's investor-relations page or SEC filings.
---
| Source | Status | Reading | Confidence |
|---|---|---|---|
| NewsAPI headline coverage | 5 headlines | All unrelated to ABT | Low |
| Social sentiment (Reddit, X, StockTwits) | Not connected | No data | Low |
| Provider sentiment score | Not supplied | - | - |
Interpretation: With no relevant news and no social-sentiment feed, the sentiment dimension of this analysis carries low confidence. The price action itself (+2.29% on moderate volume) suggests positive near-term sentiment, but we cannot corroborate this with external sentiment metrics.
---
| Scenario | Trigger condition | Confirmation | Invalidation |
|---|---|---|---|
| **Base (Consolidation)** | Price holds $95-$103 range over next 5-10 sessions | RSI14 cools toward 50-55; volume normalizes; MA20 catches up toward $94 | Close below $94.68 on heavy volume |
| **Upside (Momentum extension)** | Close above $104.17 (today's high) on volume >15 M | RSI14 remains <75; OBV turns decisively positive; new 52-week high | Reversal candle (bearish engulfing) on high volume |
| **Downside (Failed breakout)** | Close below $94.68 within 3 sessions | Breakdown confirmed if price closes below MA20 ($90.70) | Immediate reclaim of $100 on strong volume |
---
| Risk | Evidence | Trigger | Monitoring action |
|---|---|---|---|
| **Overbought mean-reversion** | Bollinger 205%, CCI 151, RSI6 70 | Daily close below $100 | Watch for bearish RSI divergence |
| **Volume non-confirmation** | Volume -26% vs 20-day avg | Continued price rise on declining volume | Track OBV slope; flag if turns negative |
| **Valuation compression** | Price 56% above DCF base case | Earnings miss or guidance cut | Monitor next earnings release and analyst revisions |
| **News vacuum** | No ABT-specific headlines | Unexpected negative headline | Set news alerts for FDA, earnings, M&A |
| **Macro / sector rotation** | Healthcare sector ETF (XLV) weakness | XLV underperforms SPY by >2% weekly | Compare ABT relative strength vs XLV |
---
1. Price vs $94.68-$95.74 zone - Does any pullback hold this former resistance as new support? 2. Volume trend - Does participation increase toward or above the 14.4 M 20-day average on up days? 3. RSI14 trajectory - Does RSI14 cross above 70 (overbought) or begin diverging negatively from price? 4. OBV slope - Does the +3% 20-session slope accelerate or flatten/reverse? 5. Company-specific news - Verify earnings date, FDA pipeline updates, or guidance revisions via Abbott IR. 6. Sector context - Monitor XLV and peer large-cap medtech names (MDT, SYK, BDX) for relative strength. 7. Macro calendar - Note any scheduled Fed commentary or healthcare-policy headlines that could affect sector sentiment.
---
This research brief is produced by StockKit for informational purposes only. It is not personalized investment advice and does not constitute a recommendation to buy, sell, or hold any security. All technical levels are observational "watch levels," not trading instructions. Valuation outputs labeled *StockKit scenario model* are internally computed forecasts, not consensus analyst targets. Data confidence varies by source as noted; users should verify critical inputs independently. Past performance is not indicative of future results, and all investing involves risk of loss.
MA5>MA20金叉，多头排列
MACD金叉，MACD在零轴上方，动能增强
RSI14=63偏高
突破上轨，短期超买
价涨量缩，上涨力度不足
Çinar Basmaci, CEO de Kentkart: "Gane quien gane en Madrid, hemos venido a quedarnos"
Expansion.com · 2026-07-26
DTM race Oschersleben 2: Bortolotti snatches victory after Manthey faux pas
Motorsport.com · 2026-07-26
DTM Oschersleben: Preining on pole again, disaster for Thiim!
Motorsport.com · 2026-07-26
Fórmula E: Mortara supera Da Costa na final e é pole no Japão
Terra.com.br · 2026-07-26
PEZ Bookshelf: Off to the Races
PezCycling News · 2026-07-26
Research boundary
StockKit organizes market data and model output for research workflows. It does not provide personalized advice or trade instructions. Verify important information with primary sources before any investment decision.